How to read the Dosage and Administration section (Section 2) of an FDA label: structure, not numbers

What this guide covers (and what it deliberately leaves out)

GLPWiki's FDA-labeling hub, How to read FDA peptide labeling, walks through the whole Prescribing Information. Our sister guides go deep on single sections: Indications and Usage (Section 1), Dosage Forms and Strengths (Section 3), Contraindications (Section 4), Warnings and Precautions with Adverse Reactions (Sections 5 and 6), Drug Interactions (7), Use in Specific Populations (8), Clinical Pharmacology (12), Patient Counseling (17) and the Highlights. Section 2 was the last numbered section in the series without its own guide.

It is also the section where a literacy guide has to be most careful. This page explains how Section 2 is organized, what the regulation requires it to contain, how FDA recommends ordering and wording it, and how it links to the rest of the label. It does not reproduce any product's doses, strengths, dose-escalation steps, intervals, missed-dose windows or injection technique, and nothing here suggests how anyone should take any medicine. When we quote a label, we quote headings or structural wording only. For the conceptual idea of gradual dose increases without numbers, see our Titration concepts explained guide.

The legal checklist: 21 CFR 201.57(c)(3)

In the Physician Labeling Rule (PLR) format, Dosage and Administration is numbered Section 2 of the Full Prescribing Information. The regulation, 21 CFR 201.57(c)(3)(i), says the section "must state the recommended dose and, as appropriate":

• (A) the dosage range
• (B) "an upper limit beyond which safety and effectiveness have not been established, or beyond which increasing the dose does not result in increasing effectiveness"
• (C) dosages for each indication and subpopulation
• (D) the intervals recommended between doses
• (E) "the optimal method of titrating dosage"
• (F) "the usual duration of treatment when treatment duration should be limited"
• (G) dosing recommendations based on clinical pharmacologic data (the regulation's example is clinically significant food effects)
• (H) modification of dosage needed because of drug interactions or in special populations (children, older adults, groups defined by genetic characteristics, or people with renal or hepatic disease)
• (I) important considerations concerning compliance with the dosage regimen
• (J) efficacious or toxic concentration ranges and therapeutic concentration windows, plus therapeutic drug monitoring information when monitoring is necessary

FDA's guidance: from the 2010 guidance to the 2023 draft

FDA first issued a guidance on this section in March 2010. In January 2023 it withdrew that document and published a draft guidance titled Dosage and Administration Section of Labeling for Human Prescription Drug and Biological Products — Content and Format (Revision 1), announced in the Federal Register on January 13, 2023. Like all draft guidance it is labeled "Contains Nonbinding Recommendations" and "Draft – Not for Implementation," and as of this review FDA's guidance page still lists it as a draft. It is still the clearest public statement of how FDA reviewers think about Section 2, and FDA staff walked through it in a 2023 Small Business and Industry Assistance webinar.

Its general principles are useful reading tools:

• Written for clinicians. The section should use "active voice and command language whenever possible" and be "pertinent and understandable to health care practitioners, which can help reduce medication errors." Detailed patient-facing steps for preparing, injecting, storing and disposing of a product typically belong in an FDA-approved Instructions for Use instead.
• Dose vs dosage. Applicants should use "dose" for "a specific amount of drug taken at one time" and "dosage" for "a specific amount of drug administered at a specific frequency (and over a certain duration, if applicable)." That is why modern headings say "Recommended Dosage."
• No "usual dose." FDA recommends avoiding "usual dose" and "usual dosage" because they "could be interpreted to refer to the most prescribed dose, which may be inconsistent with the recommended dose."
• Keep other content out. FDA generally recommends against putting contraindications or "avoid use" / "not recommended" statements, and efficacy data, in Section 2. Generic statements such as "use the optimal dosage" should also be left out.
• Cross-reference the rationale. When a recommendation rests on data elsewhere (for example, a food-effect study), Section 2 should point to that section, such as Clinical Pharmacology (12.3).
• Precise numbers, not percentages. For dosage modifications, FDA recommends stating the precise modified dosage rather than a percentage reduction, to reduce the risk of medication errors.

How Section 2 is ordered

FDA's draft guidance says the sequence should be "based on its relative clinical importance," with the most clinically relevant information first. It also recommends putting all content under numbered subsections, because text "floating" between the Section 2 heading and subsection 2.1 does not appear in the label's table of contents. Read in order, a typical modern Section 2 has up to seven zones.

• Critical information first. When not knowing or not following an instruction "could have serious consequences for patients," it should come first, with a cross-reference to the detail (often Warnings and Precautions). FDA's examples include past route-of-administration errors, required dilution, dangerous substitution between products, a required care setting, and evaluations or tests needed before starting, such as "2.x Recommended Evaluation and Testing Before Initiating DRUG-X."
• Fundamental recommended dosage. The recommended dosage for each indication, with route, any starting or loading dosage, the titration schedule, the maximum recommended dosage and duration, and administration instructions tied to the dosage (for oral drugs, the timing relative to food).
• Other therapy before, during or after. Premedication, or a concomitant therapy the drug must be used with. If the indication is adjunctive (for example, alongside a reduced-calorie diet and increased physical activity), Section 1 must say so and Section 2 often repeats it.
• Dosage modifications. Changes for adverse reactions (reduce, interrupt or discontinue) and for drug interactions, each with a pointer to Sections 5, 6, 7 or 12.
• Specific populations. Recommended dosage in renal or hepatic impairment, pediatric or geriatric patients, or genetically defined groups, but only when it differs from the general recommendation. FDA recommends headings such as "Recommended Dosage in Patients with Renal Impairment," because the shorter "Renal Impairment" is reserved for Section 8.6.
• Switching, missed doses and discontinuation. How to switch to the drug from another product or presentation, cautions against substitution, what to do after a missed dose, what to do after vomiting an oral dose, and tapering when withdrawal is a risk.
• Preparation, administration and storage of the prepared product. Reconstitution or dilution, compatible diluents, containers or devices, injection sites and rotation where relevant, the parenteral inspection statement, and how long a reconstituted product may be stored.

What GLP-1 and peptide labels actually show

Reading only the subsection headings of Section 2 across current DailyMed labels (versions checked October 28, 2026) shows how the template flexes to fit each product. We list headings only and leave out every number.

• Ozempic (semaglutide injection): 2.1 Important Administration Instructions; 2.2 Recommended Dosage. What the structure tells you: Administration rules come first; missed-dose and day-change rules sit inside 2.1.
• Rybelsus / Ozempic tablets (oral semaglutide): 2.1 Important Administration Instructions; 2.2 Recommended Starting, Escalation and Maintenance Dosage; 2.3 Switching Between RYBELSUS and OZEMPIC Tablets; 2.4 Switching from OZEMPIC Injection to RYBELSUS or OZEMPIC Tablets. What the structure tells you: Food and water timing rules lead; 2.1 states the two tablet products "are not substitutable on a mg-to-mg basis".
• Wegovy (semaglutide injection and tablets): 2.1 Important Monitoring and Administration Instructions; 2.2 Recommended Dosage for WEGOVY Injection; 2.3 Recommended Dosage of WEGOVY Tablets; 2.4 Recommendations Regarding Missed Dose(s); 2.5 Switching Between WEGOVY Injection and WEGOVY Tablets. What the structure tells you: Two presentations under one label, so dosage, missed-dose and switching rules are split by presentation.
• Mounjaro (tirzepatide): 2.1 Recommended Dosage; 2.2 Important Administration Instructions. What the structure tells you: Recommended dosage comes first; administration second.
• Zepbound (tirzepatide): 2.1 Recommended Dose Escalation Schedule; 2.2 Recommended Maintenance and Maximum Dosage; 2.3 Recommendations Regarding Missed Dose; 2.4 Important Administration Instructions. What the structure tells you: The 201.57(c)(3) items titration (E) and upper limit (B) each get a heading.
• Victoza (liraglutide): 2.1 Recommended Dosage; 2.2 Recommendations Regarding Missed Dose; 2.3 Important Administration Instructions. What the structure tells you: A compact three-part pattern.
• Saxenda (liraglutide): 2.1 Important Administration Instructions; 2.2 Dosage in Adults and Pediatric Patients Aged 12 Years and Older. What the structure tells you: Adult and adolescent recommendations share one subsection.
• Trulicity (dulaglutide): 2.1 Adult Dosage; 2.2 Pediatric Dosage; 2.3 Recommendations Regarding Missed Dose; 2.4 Important Administration Instructions. What the structure tells you: Separate subpopulation subsections, item (C).
• Byetta (exenatide): 2.1 Recommended Dosing. What the structure tells you: Older single-subsection structure.
• Soliqua 100/33 (insulin glargine and lixisenatide): 2.1 Important Dosage Information; 2.2 Recommended Starting Dose; 2.3 Titration of SOLIQUA 100/33; 2.4 Missed Doses; 2.5 Important Administration Instructions. What the structure tells you: Fixed-combination product: 2.1 explains how the units on the pen relate to each component, with a table.
• Gattex (teduglutide): 2.1 Important Administration Information; 2.2 Recommended Dosage and Administration for Adults and Pediatric Patients 1 Year of Age and Older; 2.3 Dosage Adjustment for Renal Impairment; 2.4 Monitoring to Assess Safety; 2.5 Discontinuation of Treatment; 2.6 Preparation Instructions. What the structure tells you: Pre-treatment evaluation, renal modification, safety monitoring, discontinuation and reconstitution all appear.
• Imcivree (setmelanotide): 2.1 Patient Selection; 2.2 and 2.3 Recommended Dosage by condition; 2.4 Recommended Dosage in Patients with Renal Impairment; 2.5 Administration Instructions. What the structure tells you: Patient selection by diagnosis or genotype comes first, as "critical information".

Section 2 as a cross-reference hub

Section 2 says what to do; other sections say why. FDA's guidance repeatedly asks Section 2 to point to "detailed discussions in other sections of labeling that provide the basis for recommendations." Reading Section 2 well means following its bracketed pointers, written like "[see Clinical Pharmacology (12.3)]."

• Section 1, Indications and Usage. Section 2 recommends a dosage per indication, and its subsection headings should not simply copy Section 1's indication headings (FDA suggests "2.1 Recommended Dosage for Disease-A" rather than "2.1 Disease-A").
• Section 3, Dosage Forms and Strengths. The products and strengths that the recommended dosage can be delivered with are listed in Section 3, not Section 2. Package type and presentation details generally belong in Sections 3 and 16.
• Section 5, Warnings and Precautions. Pre-treatment testing, dosage modifications for adverse reactions and "do not administer" route warnings in Section 2 point to the full risk description in Section 5. Our Warnings, Precautions and Adverse Reactions guide covers that section.
• Section 6, Adverse Reactions. When a schedule exists to reduce adverse reactions (for example, a gradual increase to reduce gastrointestinal reactions), the supporting incidence data are in Section 6 and the clinical studies in Section 14. Clinical reviews of GLP-1 gastrointestinal effects, such as Wharton et al. (2022), discuss why gradual dose increases are used, but they do not replace the product's own Section 2.
• Section 7, Drug Interactions. Section 2 includes a dosage modification for an interaction only when there is enough information to support a specific one; the mechanism and the management detail stay in Section 7.
• Section 8, Use in Specific Populations, and Section 12, Clinical Pharmacology. Renal, hepatic, pediatric and geriatric recommendations in Section 2 rest on the data in Sections 8.4 to 8.7 and 12.3. A "no adjustment" conclusion is usually explained there, not in Section 2.
• Section 14, Clinical Studies. Trials show what was studied. The STEP 1 trial of semaglutide for weight management, for example, lists its protocol's escalation steps on ClinicalTrials.gov, but a protocol is not a label instruction. Only Section 2 carries the approved regimen, and 201.57(c)(3)(ii) bars other sections from implying one.
• Section 16, How Supplied/Storage and Handling. Storage of the unopened product is in Section 16; storage of a reconstituted or diluted product, when important, is in Section 2.
• Section 17 and the Instructions for Use. Patient-facing steps are written in plain language in the FDA-approved patient labeling. FDA's July 2022 guidance on Instructions for Use describes that document as written for patients or caregivers using products with "complicated or detailed patient-use instructions."

Preparation and administration instructions: what they are and are not

Paragraph (iv) of the regulation makes preparation and administration content mandatory "if needed." The draft guidance fills in what that usually means:

• directions for reconstituting a lyophilized powder or diluting a concentrate, naming compatible diluents by their established names (for example, "0.9% Sodium Chloride Injection" rather than "saline")
• the strength of the final solution after preparation, normally in milligrams per milliliter, and the volume to withdraw
• for subcutaneous or intramuscular products, recommended injection sites and rotation "if needed"
• incompatibilities with other drugs, diluents, containers or devices, described in general terms when the device is not part of the approved application
• a brief "do not" statement for a dangerous route, with a pointer to Section 5 (the guidance's example: "Do not administer intrathecally")
• the verbatim parenteral inspection statement, and storage time for the prepared product when important

Why compounded and research products have no Section 2

Section 2 exists only in FDA-approved labeling, which is approved together with an NDA or BLA. Compounded drugs and products sold "for research use only" have no FDA-approved Prescribing Information, so there is no FDA-reviewed Section 2 to consult. Any instructions that come with them have not gone through the review that 201.57(c)(3) describes.

FDA has documented what can go wrong without that structure. In a July 2024 compounding risk alert, FDA reported adverse events, some requiring hospitalization, linked to dosing errors with compounded injectable semaglutide in multiple-dose vials. Contributing factors included patients unfamiliar with drawing medication into a syringe, instructions written in syringe "units" whose volume depends on concentration, syringes much larger than the prescribed volume, and clinicians miscalculating conversions between milligrams, milliliters and units. FDA noted that FDA-approved injectable semaglutide products "are dosed in milligrams, have standard concentrations" and were, at the time of the alert, available only in prefilled pens. FDA's broader statement on unapproved GLP-1 drugs also describes reports of compounded semaglutide or tirzepatide prescribed beyond the FDA-approved label, including faster titration. A 2023 poison-center case series (Lambson et al.) described similar administration errors and recommended more vigilance in labeling, dispensing and counseling.

FDA has separately warned that some compounders state injectable strength per milliliter more prominently than total strength per container, unlike conventional manufacturers, which has led to dosing errors with other compounded injectables. Our Dosage Forms and Strengths guide explains how approved labels express strength. The literacy lesson is simple: the safeguards described in this guide come from an approved label, and they do not carry over to a product that does not have one.

Common misreadings

• "The label says this dose, so it's the right dose for me." Section 2 is written for clinicians and states recommended dosages for an approved population. It is not an individual prescription, and the section itself often depends on monitoring, tolerability and other sections.
• "A dose in the Clinical Studies section is a recommended dose." Section 14 describes what trials tested. Under 201.57(c)(3)(ii), only Section 2 carries the regimen.
• "No renal subsection means kidney function doesn't matter." It usually means no renal dosage modification is recommended. Sections 5, 8.6 and 12.3 can still describe kidney-related risks.
• "The maximum recommended dosage is a target." Item (B) is "an upper limit beyond which safety and effectiveness have not been established, or beyond which increasing the dose does not result in increasing effectiveness." It is a ceiling, not a goal.
• "A titration schedule is a suggestion that can be sped up." FDA's guidance describes titration as increasing "incrementally to achieve effectiveness while reducing the risk of adverse reactions." Our Titration concepts guide explains the idea without numbers; the schedule itself is a prescriber's decision.
• "Missed-dose rules are the same across a drug class." They are written per product and per presentation, only when supporting information exists.
• "Switching between two products with the same ingredient is one-to-one." Some labels say the opposite; oral semaglutide's label states its tablet products "are not substitutable on a mg-to-mg basis."
• "An instruction from a clinic or seller is the same as the label." Only FDA-approved labeling for the exact product carries a Section 2.

A five-step way to read any Section 2

• Check the label version. Confirm the product, presentation and revision date on DailyMed or Drugs@FDA, and look at Recent Major Changes in Highlights for Section 2 updates.
• Read the subsection list first. Section 2's headings appear in the label's table of contents. They show at a glance whether the label has critical pre-treatment requirements, separate subpopulation dosages, switching rules, missed-dose rules or preparation steps.
• Read subsection 2.1 in full. Whatever its title, the first subsection usually holds the information FDA considers most critical to safe use.
• Follow every bracketed cross-reference. The "why" behind an instruction is in Sections 5, 7, 8, 12 or 14.
• Separate clinician text from patient text. Section 2 is written for prescribers. Patient steps are in the Medication Guide, Patient Information and Instructions for Use, and questions about a specific person belong with a clinician or pharmacist.

Scope and disclaimer

GLPWiki is an educational resource. This guide explains how the Dosage and Administration section of FDA prescription drug labeling is structured; it is not medical advice, does not provide doses, schedules or administration instructions, and does not recommend for or against any treatment. Decisions about any medicine, including whether, how much and how to take it, belong with a licensed clinician or pharmacist using the current FDA-approved labeling for the exact product. Label contents change; always check the current version. To report a suspected adverse reaction or medication error, contact the manufacturer or FDA MedWatch at 1-800-FDA-1088 or www.fda.gov/medwatch.

Last reviewed: October 28, 2026. Labeling and guidance may have changed since; verify with Drugs@FDA, DailyMed, and your pharmacist or clinician.